Amtagvi And New TIL Will Meet Aging Global Demand
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 10 Analysts
Published
20 Aug 25
Updated
20 Aug 25
AnalystHighTarget's Fair Value
US$20.00
87.4% undervalued intrinsic discount20 Aug
US$2.53
1Y
-78.6%7D
3.3%